Study of MK0476 (Montelukast Sodium) and Effects on Asthma and Nasal Symptoms Upon Exposure to Cats (0476-256)

Last updated: August 12, 2024
Sponsor: Organon and Co
Overall Status: Completed

Phase

3

Condition

Asthma

Nasal Obstruction

Allergy

Treatment

Comparator: placebo

MK0476, montelukast sodium

Clinical Study ID

NCT00092105
0476-256
2004_024
  • Ages 15-55
  • All Genders

Study Summary

The purpose of this study is to determine the protective effect of an approved medication on asthma and allergic rhinitis (inflammation of the mucous membrane of the nose) upon exposure to cats.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Increased sensitivity to cat allergen proven by positive allergy testing, and bydecreased lung function and increased symptoms of allergic rhinitis (runny nose)upon exposure to cats.

Exclusion

Exclusion Criteria:

  • Medical history of a lung disorder (other than asthma) or a recent upper respiratorytract infection.

Study Design

Total Participants: 58
Treatment Group(s): 2
Primary Treatment: Comparator: placebo
Phase: 3
Study Start date:
April 01, 2002
Estimated Completion Date:
January 28, 2003

Study Description

The duration of treatment is 2 weeks.